Bristol-Myers Squibb Company (NYSE:BMY) ranks among the most active blue chip stocks to buy now. On January 7, UBS upgraded Bristol-Myers Squibb Company (NYSE:BMY) to Buy from Neutral, raising its price target to $65 from$46. Analyst Michael Yee noted a severely skewed risk/reward ratio to the potential in the latter half of 2026, with three to four key triggers that may propel the stock up as much as 25%. Pixabay/Public Domain The firm highlighted that Bristol-Myers Squibb Company (NYSE:BMY) will face ...